These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23276932)

  • 41. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monoclonal antibodies for targeted therapy in colorectal cancer.
    Banerjee S; Flores-Rozas H
    Cancer Biol Ther; 2010 Apr; 9(8):563-71. PubMed ID: 20200482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors.
    Argyriou AA; Kalofonos HP
    Mol Med; 2009; 15(5-6):183-91. PubMed ID: 19305491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A perspective: role of targeted therapy in colon cancer].
    Chung HH; Jang BI
    Korean J Gastroenterol; 2013 Mar; 61(3):128-35. PubMed ID: 23575231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagents.
    Park NJ; Wang X; Diaz A; Goos-Root DM; Bock C; Vaught JD; Sun W; Strom CM
    PLoS One; 2013; 8(8):e71703. PubMed ID: 23990977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
    Jiang Z; Li C; Li F; Wang X
    PLoS One; 2013; 8(2):e56205. PubMed ID: 23441167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
    Slichenmyer WJ; Fry DW
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):67-79. PubMed ID: 11706398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?
    Ponz-Sarvisé M; Rodríguez J; Viudez A; Chopitea A; Calvo A; García-Foncillas J; Gil-Bazo I
    World J Gastroenterol; 2007 Nov; 13(44):5877-87. PubMed ID: 17990353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
    Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
    World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor as a target for chemotherapy.
    Vallbohmer D; Lenz HJ
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
    Assenat E; Ychou M
    Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
    Cohen DJ; Hochster HS
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S21-7. PubMed ID: 18361803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
    Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
    Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.